Product Roadmap

Performed by CureTip
Description
Our product is a service, which helps oncologists to choose drugs for patients with
lung cancer. CureTip is a test, which takes personal genomic data of particular
patient and predicts, what therapy is the most efficient for him. Thus, CureTip aims
to increase quality of cancer treatment by choosing the best set of drugs for each
patient.
CureTip uses universal algorithm and can be implemented to any type of
cancer. However, to be focused on one market, now we only deal with lung cancer
treatment. How it works:
As you see, for each patient clinician sends sample with cancer tissue to DNA
sequencing laboratories and take back information of mutations in the cancer of
this patient. Then, if he has an uncertainty which drug to choose, he sends this data
to us.
Fig.1. Life cycle use case.

We predict, what drugs work the best for this patient. As a result, we send to
clinician the list of existing drugs sorted for probable efficiency of each of this
drugs for this particular patient case. And the clinician, in his turn, uses results of
our prediction to prescribe therapy for the patient. Insurance company pays us for
the test.
Thus, as a result we provide a list of drugs with affiliated numbers - probable
efficiencies (fig. 2). It can be ordered and received electronically through web site
or e-mail and doesnt even require any real paper work.
Fig. 2. Result interpretation of our product.

Value creation
We should consider main players of Decision-Making Units (DMU) and how our
product will create value for them. Based on our interview data we can conclude
that our DMU involves three main persons: insurance company,
physician and patient.
Based on interview data we concluded that top priorities for clinicians are
accuracy of predicted results and clear interpretation of these results. The results
will contain detailed information of drug set and predicted effectiveness of each
drug from this set for particular patient. Besides, the results will be presented in a
user-friendly form, so it will be easy to interpret them. For convenience, all drugs
will be sorted by their effectiveness, so it will be very easy to define, what drug is
the best for certain patient. As the current companies dont concentrate on both of
these features, by combining them we can get an advantage over our competitors.
Assumptions for success:
(1) Our technology will provide at least 50% better prediction in terms of cured
patients;
(2) Clinicians dont know which drug will act the best in 50% of cases and have to
guess when they prescribe a treatment;
(3) Clinicians would like to use our tests for 50% of all lung cancer patients they
have;
(4) Clinicians agree to provide us with DNA tests results;
(5) Insurance companies are interested to try new technology service to decrease
costs of cancer treatment for each patient by 7% in average;
(6) Insurance companies agree to pay for product without FDA approval.

Minimum Viable Product

Our MVP - service for prediction of the best targeted drug from all FDA approved
ones for mutated EGFR receptor. It requires sequence of only one gene. It doesnt
include statistics and additional features - only our prediction. It predicts the right
drug only based on efficiency (not toxicity and side effects, this is for beta
version). Cost of Good Sold for MVP is very low, as analysis requires low amount
of processor-hours (about 16) what costs about $3 of cluster rent time.
As the number of clinicians (~80 in lung cancer in MA) is not so high and
we are going to work with each of them personally in early stage, we will get
feedbacks from clinicians directly to improve our product and add necessary
features. We are mainly interested in such information as:
1) cases where our prediction is not similar to statistical data to improve our
algorithm and analyse what caused these deviations;
2) how user-friendly is information provided by our service, what is useful and
what is not to improve convenience of our product;
3) what proteins clinicians want to be covered by our algorithm next to identify
next targets.

Further Milestones
There will be 3 main pathways of improvement: increase of number of drugs and
proteins involved in analysis; more user-friendly service to clinicians;
improvement of quality and performance of prediction.
First step of improvement will be adaptation of our system to the maximum
number of cancer-related proteins, so we can cover more patients. We are going to
collect feedback from the clinicians - that will allow to both make our output more
useful and make clinicians feel important. Also we are going to collect statistics to
provide more valuable information to our customer. At this step we expect low
4

amount of tests ordered - no more that 15 per month.

After the first improvements we are going to start working on quality
increase by improving the algorithm. As algorithm is our core it will be very
important to continuously develop it. When amount of ordered tests grows faster, it
will be necessary to improve the speed of the algorithm and its performance, so it
will be possible to do more work at the same amount of time and same
computational power. We expect to carry out more than 100 tests per month on this
stage.
In the long term we are going to include more services - such as new drug
analysis for pharmaceutical companies. Other pathway for the long term is to make
predictions not only FDA approved drugs but also the drugs on the clinical trials.
That will allow clinicians to choose the best drug from all existing ones and
provide patient with the best targeted choice.